+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028

  • PDF Icon

    Report

  • 118 Pages
  • April 2021
  • Region: Africa, Middle East
  • Triton Market Research
  • ID: 5311023

MARKET OUTLOOK

This report suggests that the Middle East and Africa non-alcoholic steatohepatitis (NASH) biomarker market is assessed to exhibit revenue growth at a CAGR of 21.48% in the period 2021-2028. South Africa, Turkey, the UAE, Saudi Arabia, and Rest of Middle East & Africa form the market in this region.
In Turkey, medical tourism is rising at a rapid pace, with weight-loss surgeries offered at an affordable cost. This has attracted several patients to travel to turkey to undergo weight loss surgery. Furthermore, non-alcoholic fatty liver disease is growing significantly, considering the high levels of obesity across the country. Here, the growth in obesity rates leads to the development of non-alcoholic fatty liver disease in some cases. Hence, the high prevalence of obesity, along with increasing medical tourism for weight loss surgeries, is estimated to generate several new opportunities for the non-alcoholic steatohepatitis biomarker market in Turkey in the next few years.

Similarly, the majority of the South African population suffers from diabetes, which is leading to the rise in the cases of NASH. Moreover, as per studies, a large number of people are obese, which is also increasing the prevalence of NASH in the country. Furthermore, the country has the highest obesity rates in the sub-Saharan Africa region. This indicates that the growing incidence of obesity and diabetes is likely to supplement the growth of the NASH biomarker market within South Africa.

COMPETITIVE OUTLOOK

The companies established in the NASH biomarker market are Zydus Cadila, Siemens Healthineers, Pfizer Inc, AstraZeneca, Novo Nordisk, and Allergan.

Table of Contents

1. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Summary
2. Industry Outlook
2.1. Key Insights
2.1.1. Demand for NASH Biomarkers
2.1.2. Unmet Medical Needs
2.2. Impact of COVID-19 on Non-Alcoholic Steatohepatitis (NASH) Biomarker Market
2.3. Porter's Five Forces Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitute Products
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Competitive Rivalry
2.4. Market Attractiveness Index
2.5. Vendor Landscape
2.6. Key Market Strategies
2.6.1. Contracts & Partnerships
2.6.2. Business Expansions & Divestitures
2.6.3. Acquisitions & Mergers
2.6.4. New Product Launches
2.7. Market Drivers
2.7.1. Rising Prevalence of NASH
2.7.2. Increasing Incidence Rate of Metabolic Comorbidities
2.8. Market Restraints
2.8.1. Side-Effects of NASH Therapeutics
2.8.2. Unavailability of Specialized Diagnostic Test for Non-Alcoholic Fatty Liver Disease (Nafld)
2.9. Market Opportunities
2.9.1. Growth Opportunities in Developing Regions
2.9.2. Rise in Awareness Pertaining to Non-Alcoholic Fatty Liver Disease
3. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Type
3.1. Serum Biomarker
3.2. Hepatic Fibrosis Biomarker
3.3. Apoptosis Biomarker
3.4. Oxidative Stress Biomarker
3.5. Other Types
4. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - by Industry Verticals
4.1. Pharma & Cro Industry
4.2. Diagnostic Lab
4.3. Academic Research Key
4.4. Hospital
5. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market - Country Outlook
5.1. Saudi Arabia
5.2. United Arab Emirates
5.3. Turkey
5.4. South Africa
5.5. Rest of Middle East & Africa
6. Competitive Landscape
6.1. Allergan
6.2. Astrazeneca
6.3. Bristol Myers Squibb Company
6.4. Genfit Sa
6.5. Gilead Sciences Inc
6.6. Madrigal Pharmaceuticals
6.7. Merck & Co
6.8. Novartis AG
6.9. Novo Nordisk
6.10. Pfizer Inc
6.11. Siemens Healthineers
6.12. Viking Therapeutics
6.13. Zydus Cadila
7. Research Methodology & Scope
7.1. Research Scope & Deliverables
7.1.1. Objectives of Study
7.1.2. Scope of Study
7.2. Sources of Data
7.2.1. Primary Data Sources
7.2.2. Secondary Data Sources
7.3. Research Methodology
7.3.1. Evaluation of Proposed Market
7.3.2. Identification of Data Sources
7.3.3. Assessment of Market Determinants
7.3.4. Data Collection
7.3.5. Data Validation & Analysis
List of Tables
Table 1: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)
Table 2: Vendor Landscape
Table 3: List of Contracts & Partnerships
Table 4: List of Business Expansions & Divestitures
Table 5: List of Acquisitions & Mergers
Table 6: List of New Product Launches
Table 7: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2021-2028 (In $ Million)
Table 8: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2021-2028 (In $ Million)
Table 9: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, Country Outlook, 2021-2028 (In $ Million)
List of Figures
Figure 1: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 2: Porter's Five Forces Analysis
Figure 3: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Type, 2020 & 2028 (In %)
Figure 4: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Serum Biomarker, 2021-2028 (In $ Million)
Figure 5: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Hepatic Fibrosis Biomarker, 2021-2028 (In $ Million)
Figure 6: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Apoptosis Biomarker, 2021-2028 (In $ Million)
Figure 7: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Oxidative Stress Biomarker, 2021-2028 (In $ Million)
Figure 8: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Other Types, 2021-2028 (In $ Million)
Figure 9: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Industry Verticals, 2020 & 2028 (In %)
Figure 10: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Pharma & Cro Industry, 2021-2028 (In $ Million)
Figure 11: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Diagnostic Lab, 2021-2028 (In $ Million)
Figure 12: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Academic Research Key, 2021-2028 (In $ Million)
Figure 13: Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market, by Hospital, 2021-2028 (In $ Million)
Figure 14: Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 15: United Arab Emirates Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 16: Turkey Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 17: South Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)
Figure 18: Rest of Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Biomarker Market 2021-2028 (In $ Million)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan
  • Astrazeneca
  • Bristol Myers Squibb Company
  • Genfit Sa
  • Gilead Sciences Inc
  • Madrigal Pharmaceuticals
  • Merck & Co
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc
  • Siemens Healthineers
  • Viking Therapeutics
  • Zydus Cadila

Methodology

Loading
LOADING...